Cala Health has collaborated with the University of California, San Francisco (UCSF), US, to develop tailored peripheral nerve stimulation treatments based on the former’s neuromodulation and data science platform technology.

A bioelectronic medicine company, Cala Health combines innovations in neuroscience and technology to create wearable therapies for chronic diseases.

As part of the alliance, the company will collaborate with UCSF Weill Institute of Neuroscience neurology associate professor and neural engineering expert Dr Karunesh Ganguly, as well as others, to develop non-invasive therapies for critical neurological diseases.

Cala Health founder and chief scientific officer Kate Rosenbluth said: “Dr Ganguly’s pioneering research on the precise targeting of electrical stimulation to modulate neural networks provides an exciting path to personalise therapy to each patient.

“This partnership takes Cala Health one step closer to reaching our goal to give the millions of patients suffering from debilitating neurological disorders access to non-invasive, efficacious therapies that improve their quality of life.”

The technologies licenced from UCSF under this collaboration will aid Cala Health to grow its pipeline of neurology treatments.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Furthermore, the collaboration will boost the company’s mechanistic research to create new tailored treatments as well as aiding in incorporating its data science platform to develop software-enabled customised treatment insights for patients in a timely manner.

Ganguly said: “In my clinical work, I see the profound impacts of motor impairments from a wide range of neurological conditions such as brain injury and Parkinson’s disease, and we are committed to advancing new treatments to enhance motor function.

“The UCSF team looks forward to a fruitful partnership with Cala to advance peripheral nerve stimulation as a treatment to improve motor function.”

Recently, Cala Health introduced its transcutaneous afferent patterned stimulation therapy, Cala Trio, for treating hand tremors in the movement disorder essential tremor.